Immupharma PLC Holding(s) in Company (6574Y)

TIDMIMM

RNS Number : 6574Y

Immupharma PLC

06 March 2017

 
   6 March 2017 
 
 

ImmuPharma PLC

("ImmuPharma" or the "Company")

Holding(s) in Company

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Alto Invest now holds 4,969,543 ordinary shares of 10p each in the Company, representing 3.99% of the Company's issued share capital with voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

-Ends-

 
 For further information please 
  contact: 
                                           + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Northland Capital Partners Limited 
    (NOMAD & Broker) 
    Patrick Claridge, David Hignell, 
    Michael Mackintosh, Corporate 
    Finance                               [phone] 
    Rob Rees, Corporate Broking                6625 
 

Notes to Editors

ImmuPharma PLC

ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

Lupuzor(TM)

Lupuzor(TM) (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor(TM) has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.

Lupuzor(TM) has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.

The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor

Commercial Opportunity

There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor(TM). Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor(TM) would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor(TM) please visit: www.lupuzor.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLEQLFBDXFEBBZ

(END) Dow Jones Newswires

March 06, 2017 10:55 ET (15:55 GMT)